Amezalpat (E8300-1mg)

Amezalpat is a first-in-class, oral, competitive antagonist of peroxisome proliferator-activated receptor α (PPARα), with IC50 of 0.04 µM. It inhibits fatty acid oxidation (FAO), disrupting cancer cell metabolism and restoring immune responses, and shows antitumor activity in research on advanced solid tumors.